MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

33.51 -2.02 (-5.70%)
Streaming Delayed Price Updated: 3:15 PM EDT, Mar 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound ↗
Via Stocktwits
News headline image
Eli Lilly Shares Tumble After Disappointing Weight-Loss Pill Data
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a dramatic decline today, plummeting by more than 14% in early trading, wiping out approximately $98... 
Via MarketMinute
News headline image
Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the... 
Via MarketMinute
Topics Economy
News headline image
Earnings Scheduled For July 23, 2025 ↗
 
Via Benzinga
News headline image
A Look Ahead: Viking Therapeutics's Earnings Forecast ↗
 
Via Benzinga
News headline image
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors ↗
Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates. 
Via Benzinga
News headline image
Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge. ↗
An analyst called the unexpected flop a "once-in-a-blue-moon" occasion for Eli Lilly's dominant weight-loss franchise. 
Via Investor's Business Daily
News headline image
Is It Time to Buy Biotech Stocks? ↗
A surge in private market investment has investors wondering: Is it time to bet bigger on biotech? 
Via The Motley Fool
News headline image
This Biotech Stock Could Soar on Upcoming Clinical Data ↗
This weight loss drugmaker may be significantly undervalued right now. 
Via The Motley Fool
News headline image
2 Beaten-Down Stocks With Incredible Upside Potential ↗
Getting in on the ground floor with these companies might lead to superior returns. 
Via The Motley Fool
News headline image
2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts ↗
These biotech businesses look compelling for very different reasons. 
Via The Motley Fool
News headline image
Is Viking Therapeutics the Next Big Biotech Bet? ↗
Via The Motley Fool
News headline image
Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets ↗
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
News headline image
Tesla Posts Downbeat Earnings, Joins Community Health Systems, Chipotle Mexican Grill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Viking Therapeutics Posts Wider Q2 Loss ↗
Via The Motley Fool
News headline image
Viking Therapeutics Stock Slides After Company Misses Q2 Earnings Estimates ↗
Viking Therapeutics shares fall in Wednesday's after-hours session after the company reported financial results for the second quarter. 
Via Benzinga
News headline image
Viking (VKTX) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Viking Therapeutics Inc (NASDAQ:VKTX) Posts Wider Q2 2025 Loss, Shares Drop in After-Hours Trading ↗
Viking Therapeutics reports wider Q2 2025 loss, missing EPS estimates, causing a 5.7% after-hours dip. Focus remains on clinical pipeline progress amid revenue challenges. 
Via Chartmill
News headline image
Better Growth Buy: Eli Lilly vs. Viking Therapeutics ↗
Via The Motley Fool
News headline image
3 Monster Stocks in the Making to Buy Right Now ↗
Via The Motley Fool
News headline image
These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy? ↗
Via The Motley Fool
News headline image
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. ↗
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Best Stocks to Invest $1,000 In Right Now ↗
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Better Growth Buy: Eli Lilly vs. Viking Therapeutics ↗
Via The Motley Fool
News headline image
Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Beaten-Down Stocks With Massive Upside Potential ↗
Via The Motley Fool
News headline image
10 Incredible Growth Stocks Poised for Long-Term Gains ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Got $200? 2 Biotech Stocks to Buy and Hold Forever ↗
Via The Motley Fool
News headline image
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? ↗
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story